Lack of Population Diversity in Commonly Used Human Embryonic Stem-Cell Lines

University of Michigan, Ann Arbor, MI, Masaryk University, Brno, Czech Republic, Valencia University, Valencia, Spain, University of Michigan, Ann Arbor, MI, .
New England Journal of Medicine (Impact Factor: 54.42). 12/2009; 362(2):183-5. DOI: 10.1056/NEJMc0910371
Source: PubMed
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The enormous potential of human embryonic stem cells is fueling continuous research aimed at establishment of new lines of these cells. Currently research groups from 24 countries have reported derivation of over 1000 human embryonic stem cell lines. Because of the controversy surrounding the derivation of these cells from human embryos it is important to clarify whether the existing hESC lines are sufficient for basic research and future therapeutic applications. Here we briefly review some of the most important arguments justifying the need for continuing derivation of human embryonic stem cell lines.
    Biotechnology & Biotechnological Equipment 08/2010; 24(3):1921-1927. DOI:10.2478/V10133-010-0071-X · 0.38 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Human stem cell research represents an exceptional opportunity for regenerative medicine and the surgical reconstruction of the craniomaxillofacial complex. The correct architecture and function of the vastly diverse tissues of this important anatomical region are critical for life supportive processes, the delivery of senses, social interaction and aesthetics. Craniomaxillofacial tissue loss is commonly associated with inflammatory responses of the surrounding tissue, significant scarring, disfigurement and psychological sequelae as an inevitable consequence. The in vitro production of fully functional cells for skin, muscle, cartilage, bone and neurovascular tissue formation from human stem cells, may one day provide novel materials for the reconstructive surgeon operating on patients with both hard and soft tissue deficit due to cancer, congenital disease or trauma. However the clinical translation of human stem cell technology, including the application of human pluripotent stem cells (hPSCs) in novel regenerative therapies, faces several hurdles which must be solved in order to permit safe and effective use in patients. The basic biology of hPSCs remains to be fully elucidated and concerns of tumourigenicity need to be addressed, prior to the development of cell transplantation treatments. Furthermore, functional comparison of in vitro generated tissue to their in vivo counterparts will be necessary for confirmation of maturity and suitability for application in reconstructive surgery. Here we provide an overview of human stem cells in disease modelling, drug screening and therapeutics, whilst also discussing the application of regenerative medicine for craniomaxillofacial tissue deficit and surgical reconstruction.
    Stem cells and development 02/2014; 23(13). DOI:10.1089/scd.2013.0576 · 4.20 Impact Factor
  • Journal of Policy Analysis and Management 06/2012; 31(3). DOI:10.1002/pam.21613 · 0.93 Impact Factor